MANNKIND CORP Net Income (Loss) Attributable to Parent, Diluted
MANNKIND CORP (MNKD) reported Net Income (Loss) Attributable to Parent, Diluted of -$2.01 million for the 3-month period ending 2024-06-30, per its 10-Q filed 2024-08-07.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAttributableToParentDiluted · last filed 2024-08-07
- MANNKIND CORP net income (loss) attributable to parent, diluted for the quarter ending 2024-06-30 was -$2.01M.
- MANNKIND CORP net income (loss) attributable to parent, diluted for the quarter ending 2024-03-31 was $10.63M.
- MANNKIND CORP net income (loss) attributable to parent, diluted for the quarter ending 2023-09-30 was $3.58M.
- MANNKIND CORP net income (loss) attributable to parent, diluted for the quarter ending 2023-06-30 was -$5.26M.
| Period end | Net Income (Loss) Attributable to Parent, Diluted 3 month | Net Income (Loss) Attributable to Parent, Diluted 6 month | Net Income (Loss) Attributable to Parent, Diluted 9 month |
|---|---|---|---|
| 2024-06-30 | -$2.01M 10-Q · filed 2024-08-07 | $8.62M 10-Q · filed 2024-08-07 | |
| 2024-03-31 | $10.63M 10-Q · filed 2024-05-08 | ||
| 2023-09-30 | $3.58M 10-Q · filed 2023-11-07 | -$1.69M derived: sum of 2 quarters · filed 2024-08-07 | -$13.34M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$5.26M 10-Q · filed 2024-08-07 | -$15.06M 10-Q · filed 2024-08-07 | |
| 2023-03-31 | -$9.79M 10-Q · filed 2024-05-08 | ||
| 2022-09-30 | -$14.43M 10-Q · filed 2023-11-07 | -$69.45M 10-Q · filed 2023-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |